Gilead grants Bristol-Myers Squibb (BMS) worldwide rights to a fixed-dose HIV combination therapy of BMS' Reyataz atazanavir and Gilead's cobicistat

Gilead Sciences Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$32,141.2m on 10/28/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Bristol-Myers Squibb Co.

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced